Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Forest desmoteplase

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

Forest is initiating a Phase IIb/III study of its stroke agent desmoteplase "to confirm expanded nine-hour treatment window seen in two Phase II studies," the company says Feb. 7. Current treatment (Activase) has a three-hour window. The Desmoteplase in Acute Ischemic Stroke (DIAS2) parallel-design, dose-ranging study will enroll over 150 patients. Data from the DEDAS study, presented at the International Stroke Conference Feb. 4, showed that the novel plasminogen activator improved clinical outcome after 90 days versus placebo, Forest says, although the trial was not powered to show statistical differences. Desmoteplase is derived from the saliva of vampire bats...
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS002782

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel